Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-4321 phase 1/2 study in healthy adults and adults with chronic hepatitis delta
2025-522729-36-00Phase 2Authorised
- Sponsor
- Gilead Sciences
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2 trial of GS-4321 in hepatitis D (HDV) (6 arms), sponsored by Gilead Sciences. Primary endpoints: Safety and tolerability, Pharmacokinetics of GS-4321 and 1 more. Planned start Mar 2026; status: authorised.
02
Drugs
GS-4321
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on 2025-522729-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522729-36-00.